NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) and Shineco (NASDAQ:SISI – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Institutional and Insider Ownership
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 4.1% of Shineco shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 0.0% of Shineco shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares NewAmsterdam Pharma and Shineco”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NewAmsterdam Pharma | $22.50 million | 174.33 | -$203.82 million | ($1.73) | -19.72 |
| Shineco | $9.60 million | 0.01 | -$22.45 million | ($204.00) | 0.00 |
Shineco has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NewAmsterdam Pharma and Shineco’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NewAmsterdam Pharma | -906.22% | -26.67% | -24.82% |
| Shineco | -380.55% | -79.89% | -33.01% |
Risk and Volatility
NewAmsterdam Pharma has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Comparatively, Shineco has a beta of -1.33, suggesting that its share price is 233% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for NewAmsterdam Pharma and Shineco, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
NewAmsterdam Pharma currently has a consensus price target of $48.00, indicating a potential upside of 40.68%. Given NewAmsterdam Pharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than Shineco.
Summary
NewAmsterdam Pharma beats Shineco on 12 of the 15 factors compared between the two stocks.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
